Research ArticleArticle
High-frequency Ultrasound Assessment of Systemic Sclerosis Skin Involvement: Intraobserver Repeatability and Relationship With Clinician Assessment and Dermal Collagen Content
Victoria A. Flower, Shaney L. Barratt, Darren J. Hart, Amanda B. Mackenzie, Jacqueline A. Shipley, Stephen G. Ward and John D. Pauling
The Journal of Rheumatology November 2020, jrheum.200234; DOI: https://doi.org/10.3899/jrheum.200234
Victoria A. Flower
This work was supported by Scleroderma & Raynaud’s UK. V.A. Flower, Consultant Rheumatologist, MBBS, PhD, J.D. Pauling, Consultant Rheumatologist and Senior Lecturer, BMBS, PhD, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.L. Barratt, BMBS, PhD, Department of Respiratory Medicine, North Bristol NHS Trust, Bristol, Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol; D.J. Hart, Clinical Scientist, PhD, J.A. Shipley, Clinical Scientist, PhD, Clinical Measurement and Imaging Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath; A.B. Mackenzie, Senior Lecturer, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.G. Ward, Professor, PhD, Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. JDP has received speaker’s honoraria and research grant support (> $10,000) from Actelion Pharmaceuticals and has undertaken consultancy work for Actelion Pharmaceuticals and Boehringer Ingelheim. SLB has received educational support and has undertaken consultancy work for Boehringer Ingelheim. ABM has received funding from UCB, Janssen, and Pfizer; and holds shares in Ikusda Therapeutics. SGW has received funding from UCB, Pfizer, Novartis, GSK, and Boehringer Ingelheim. VAF, DJH, and JAS have no conflicts of interests. Address correspondence to Dr. V.A. Flower, The Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. Email: v.flower@nhs.net. Accepted for publication October 16, 2020.
Shaney L. Barratt
This work was supported by Scleroderma & Raynaud’s UK. V.A. Flower, Consultant Rheumatologist, MBBS, PhD, J.D. Pauling, Consultant Rheumatologist and Senior Lecturer, BMBS, PhD, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.L. Barratt, BMBS, PhD, Department of Respiratory Medicine, North Bristol NHS Trust, Bristol, Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol; D.J. Hart, Clinical Scientist, PhD, J.A. Shipley, Clinical Scientist, PhD, Clinical Measurement and Imaging Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath; A.B. Mackenzie, Senior Lecturer, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.G. Ward, Professor, PhD, Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. JDP has received speaker’s honoraria and research grant support (> $10,000) from Actelion Pharmaceuticals and has undertaken consultancy work for Actelion Pharmaceuticals and Boehringer Ingelheim. SLB has received educational support and has undertaken consultancy work for Boehringer Ingelheim. ABM has received funding from UCB, Janssen, and Pfizer; and holds shares in Ikusda Therapeutics. SGW has received funding from UCB, Pfizer, Novartis, GSK, and Boehringer Ingelheim. VAF, DJH, and JAS have no conflicts of interests. Address correspondence to Dr. V.A. Flower, The Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. Email: v.flower@nhs.net. Accepted for publication October 16, 2020.
Darren J. Hart
This work was supported by Scleroderma & Raynaud’s UK. V.A. Flower, Consultant Rheumatologist, MBBS, PhD, J.D. Pauling, Consultant Rheumatologist and Senior Lecturer, BMBS, PhD, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.L. Barratt, BMBS, PhD, Department of Respiratory Medicine, North Bristol NHS Trust, Bristol, Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol; D.J. Hart, Clinical Scientist, PhD, J.A. Shipley, Clinical Scientist, PhD, Clinical Measurement and Imaging Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath; A.B. Mackenzie, Senior Lecturer, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.G. Ward, Professor, PhD, Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. JDP has received speaker’s honoraria and research grant support (> $10,000) from Actelion Pharmaceuticals and has undertaken consultancy work for Actelion Pharmaceuticals and Boehringer Ingelheim. SLB has received educational support and has undertaken consultancy work for Boehringer Ingelheim. ABM has received funding from UCB, Janssen, and Pfizer; and holds shares in Ikusda Therapeutics. SGW has received funding from UCB, Pfizer, Novartis, GSK, and Boehringer Ingelheim. VAF, DJH, and JAS have no conflicts of interests. Address correspondence to Dr. V.A. Flower, The Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. Email: v.flower@nhs.net. Accepted for publication October 16, 2020.
Amanda B. Mackenzie
This work was supported by Scleroderma & Raynaud’s UK. V.A. Flower, Consultant Rheumatologist, MBBS, PhD, J.D. Pauling, Consultant Rheumatologist and Senior Lecturer, BMBS, PhD, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.L. Barratt, BMBS, PhD, Department of Respiratory Medicine, North Bristol NHS Trust, Bristol, Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol; D.J. Hart, Clinical Scientist, PhD, J.A. Shipley, Clinical Scientist, PhD, Clinical Measurement and Imaging Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath; A.B. Mackenzie, Senior Lecturer, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.G. Ward, Professor, PhD, Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. JDP has received speaker’s honoraria and research grant support (> $10,000) from Actelion Pharmaceuticals and has undertaken consultancy work for Actelion Pharmaceuticals and Boehringer Ingelheim. SLB has received educational support and has undertaken consultancy work for Boehringer Ingelheim. ABM has received funding from UCB, Janssen, and Pfizer; and holds shares in Ikusda Therapeutics. SGW has received funding from UCB, Pfizer, Novartis, GSK, and Boehringer Ingelheim. VAF, DJH, and JAS have no conflicts of interests. Address correspondence to Dr. V.A. Flower, The Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. Email: v.flower@nhs.net. Accepted for publication October 16, 2020.
Jacqueline A. Shipley
This work was supported by Scleroderma & Raynaud’s UK. V.A. Flower, Consultant Rheumatologist, MBBS, PhD, J.D. Pauling, Consultant Rheumatologist and Senior Lecturer, BMBS, PhD, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.L. Barratt, BMBS, PhD, Department of Respiratory Medicine, North Bristol NHS Trust, Bristol, Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol; D.J. Hart, Clinical Scientist, PhD, J.A. Shipley, Clinical Scientist, PhD, Clinical Measurement and Imaging Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath; A.B. Mackenzie, Senior Lecturer, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.G. Ward, Professor, PhD, Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. JDP has received speaker’s honoraria and research grant support (> $10,000) from Actelion Pharmaceuticals and has undertaken consultancy work for Actelion Pharmaceuticals and Boehringer Ingelheim. SLB has received educational support and has undertaken consultancy work for Boehringer Ingelheim. ABM has received funding from UCB, Janssen, and Pfizer; and holds shares in Ikusda Therapeutics. SGW has received funding from UCB, Pfizer, Novartis, GSK, and Boehringer Ingelheim. VAF, DJH, and JAS have no conflicts of interests. Address correspondence to Dr. V.A. Flower, The Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. Email: v.flower@nhs.net. Accepted for publication October 16, 2020.
Stephen G. Ward
This work was supported by Scleroderma & Raynaud’s UK. V.A. Flower, Consultant Rheumatologist, MBBS, PhD, J.D. Pauling, Consultant Rheumatologist and Senior Lecturer, BMBS, PhD, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.L. Barratt, BMBS, PhD, Department of Respiratory Medicine, North Bristol NHS Trust, Bristol, Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol; D.J. Hart, Clinical Scientist, PhD, J.A. Shipley, Clinical Scientist, PhD, Clinical Measurement and Imaging Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath; A.B. Mackenzie, Senior Lecturer, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.G. Ward, Professor, PhD, Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. JDP has received speaker’s honoraria and research grant support (> $10,000) from Actelion Pharmaceuticals and has undertaken consultancy work for Actelion Pharmaceuticals and Boehringer Ingelheim. SLB has received educational support and has undertaken consultancy work for Boehringer Ingelheim. ABM has received funding from UCB, Janssen, and Pfizer; and holds shares in Ikusda Therapeutics. SGW has received funding from UCB, Pfizer, Novartis, GSK, and Boehringer Ingelheim. VAF, DJH, and JAS have no conflicts of interests. Address correspondence to Dr. V.A. Flower, The Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. Email: v.flower@nhs.net. Accepted for publication October 16, 2020.
John D. Pauling
This work was supported by Scleroderma & Raynaud’s UK. V.A. Flower, Consultant Rheumatologist, MBBS, PhD, J.D. Pauling, Consultant Rheumatologist and Senior Lecturer, BMBS, PhD, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.L. Barratt, BMBS, PhD, Department of Respiratory Medicine, North Bristol NHS Trust, Bristol, Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol; D.J. Hart, Clinical Scientist, PhD, J.A. Shipley, Clinical Scientist, PhD, Clinical Measurement and Imaging Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath; A.B. Mackenzie, Senior Lecturer, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath; S.G. Ward, Professor, PhD, Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. JDP has received speaker’s honoraria and research grant support (> $10,000) from Actelion Pharmaceuticals and has undertaken consultancy work for Actelion Pharmaceuticals and Boehringer Ingelheim. SLB has received educational support and has undertaken consultancy work for Boehringer Ingelheim. ABM has received funding from UCB, Janssen, and Pfizer; and holds shares in Ikusda Therapeutics. SGW has received funding from UCB, Pfizer, Novartis, GSK, and Boehringer Ingelheim. VAF, DJH, and JAS have no conflicts of interests. Address correspondence to Dr. V.A. Flower, The Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. Email: v.flower@nhs.net. Accepted for publication October 16, 2020.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
High-frequency Ultrasound Assessment of Systemic Sclerosis Skin Involvement: Intraobserver Repeatability and Relationship With Clinician Assessment and Dermal Collagen Content
Victoria A. Flower, Shaney L. Barratt, Darren J. Hart, Amanda B. Mackenzie, Jacqueline A. Shipley, Stephen G. Ward, John D. Pauling
The Journal of Rheumatology Nov 2020, jrheum.200234; DOI: 10.3899/jrheum.200234
High-frequency Ultrasound Assessment of Systemic Sclerosis Skin Involvement: Intraobserver Repeatability and Relationship With Clinician Assessment and Dermal Collagen Content
Victoria A. Flower, Shaney L. Barratt, Darren J. Hart, Amanda B. Mackenzie, Jacqueline A. Shipley, Stephen G. Ward, John D. Pauling
The Journal of Rheumatology Nov 2020, jrheum.200234; DOI: 10.3899/jrheum.200234